Medidata adding eConsent via Mytrus acquisition

By Melissa Fassbender

- Last updated on GMT

Mytrus is a privately held e-clinical technology company. (Image: iStock/ismagilov)
Mytrus is a privately held e-clinical technology company. (Image: iStock/ismagilov)

Related tags Patient Informed consent

Medidata is set to acquire Mytrus, Incorporated – adding eConsent and remote monitoring solutions for a "modern trial experience."

The acquisition, terms of which were not disclosed, is expected to be completed in April 2017.

Informed consent is a critical component to any clinical trial, as it provides patients with the right information to allow for an educated decision about participating in an investigative study​, Kara Dennis, Medidata's Managing Director of Mobile Health (mHealth), told

Additionally, Mytrus’ Enroll enables trial monitors to track consents remotely, which it says reduces on-site monitoring activity.

Adding eConsent to Medidata Patient Cloud is a natural next step in the continued evolution of our mobile health offering, further improving the patient experience as well as streamlining the trial monitoring process​,” Dennis explained.

Medidata’s comprehensive mHealth solution enables a modern trial experience by allowing sponsors, sites and patients to make use of best-in-class technology to support trial operations and participation​.”

According to Dennis, Enroll can be provided as an iOS-based native solution used by sites or as a web-based solution accessible to patients or site staff.

The technology will be integrated with the Medidata platform and joins AppConnect, SensorLink, and ePRO as the fourth module in Medidata Patient Cloud.

Strategic investments

Medidata’s focus is to drive organic growth through innovation, Dennis said. “In 2016, we reinvested over 24% of revenue into R&D to enhance and expand our industry-leading platform​,” she added.

In regards to M&A, Dennis said the company’s strategy is to supplement organic growth with strategic tuck-in deals that either enhance existing capabilities or accelerate the development of new solutions on the platform.

We have been very disciplined with this approach as those have seen with our acquisition of Patient Profiles (2014), Intelemage (2016), and, most recently, Chita and Mytrus (2017)​,” she added.

We have a strong balance sheet and can continue to invest strategically when we identify compelling opportunities to enhance the value of our platform in areas such as data analytics, machine learning and mobile health, for example​.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more